If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIncanthera Regulatory News (INC.PL)

Share Price Information for Incanthera (INC.PL)

Share Price is delayed by 15 minutes
Get Live Data
1.75    0.00 (0.00%)
Bid:
1.50
Ask:
2.00
Spread: 0.50 (33.333%)
Market Cap: £2.66m
INC.PL Live PriceLast checked at - Aquis Stock Exchange

Intraday Incanthera Share Chart

Holding(s) in Company

6 Jun 2024 16:20

RNS Number : 4761R
Incanthera PLC
06 June 2024
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Incanthera PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

ImmuPharma PLC

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

3/6/2024

6. Date on which issuer notified (DD/MM/YYYY):

6/6/2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

0.00%

0.00%

0.00%

0

Position of previous notification (if

applicable)

9.98%

0.00%

9.98%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB0033711010

SUBTOTAL 8. A

0

0.00%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

London

Date of completion

6/6/2024

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXEQLFBZQLFBBB
12
Date   Source Headline
12th Jun 20264:30 pmRNSHolding(s) in Company
4th Jun 20267:00 amRNSCorporate Update
31st Mar 20267:00 amRNSCommercial Update
11th Dec 20257:20 amRNSHalf-year Report
17th Nov 20257:00 amRNS-RAquis Showcase Investor Presentation
10th Nov 202511:04 amRNS-RAGM 2025 Presentation Materials
7th Nov 20252:30 pmRNSResult of AGM
6th Nov 20257:00 amRNSAGM 2025 Update
16th Oct 202510:15 amRNS-RProactive Investor Forum Presentation
14th Oct 20257:00 amRNSNotice of AGM
6th Oct 20257:00 amRNS-RInvestor Presentation
30th Sep 20258:15 amRNSFinal Results
11th Aug 20257:00 amRNSSKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
6th Aug 20257:00 amRNSSKIN + CELL TO LAUNCH
9th Jul 20257:00 amRNSHolding(s) in Company
30th Jun 20257:00 amRNSSubscription, Directors' Dealing and RPT
18th Jun 20257:00 amRNSNew Findings on Protective Effects of Skin + CELL
2nd Jun 20257:00 amRNSDirect To Customer Agency Agreement Completed
22nd May 20257:00 amRNSCommercial Update
8th Apr 20257:00 amRNSHolding(s) in Company
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
28th Mar 20257:00 amRNSCommercial Update
25th Mar 20253:08 pmRNSResolution of Allegations of Patent Infringement
18th Dec 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSCommercial Update
29th Oct 20247:00 amRNSFurther re: Commercial Update
17th Oct 20241:05 pmRNSResult of AGM
26th Sep 20247:00 amRNSCommercial Update
25th Sep 20247:00 amRNSNotice of AGM
9th Sep 20247:01 amRNSExtension of Warrants
27th Aug 20247:00 amRNSFinal Results
14th Aug 20247:00 amRNSExercise of Warrants
11th Jul 20247:00 amRNSCommercial Order Update
25th Jun 20244:00 pmRNSHolding(s) in Company
21st Jun 20242:45 pmRNSHolding(s) in Company
21st Jun 20248:00 amRNSCompletion of Subscription
20th Jun 202411:38 amRNSResult of Meeting
10th Jun 20247:00 amRNSAppointment of NED & Promotion to the Apex Segment
6th Jun 20244:20 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNSAQSE Webinar Presentation
3rd Jun 20247:00 amRNSCommercial Update and Subscription
16th May 20248:07 amRNSInvestor Presentation
25th Apr 20247:00 amRNSHolding(s) in Company
23rd Apr 20242:15 pmRNSFurther re: Exercise of Warrants
17th Apr 20247:00 amRNSFurther re: Exercise of Warrants
9th Apr 20243:00 pmRNSExercise of Warrants
25th Mar 20242:30 pmRNSInitiation of Analyst Research and IGTV Interview
25th Mar 20247:00 amRNSCommercial Update
22nd Feb 20247:00 amRNSGrant of Options
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.